World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
96
Citations
49307
World Ranking
9495
National Ranking
924

Overview

John P.H. Wilding is affiliated with the University of Liverpool in the United Kingdom. Their research focuses primarily on medicine, with significant contributions in biochemistry, genetics, and molecular biology. A considerable portion of their work is concentrated in the subfields of endocrinology, diabetes, and metabolism, as well as molecular biology, surgery, physiology, and pharmacology.

The scientist's main topics of research include diabetes treatment and management, metabolism in relation to diabetes and cancer, pharmacology and obesity treatment, pancreatic function and diabetes, diet and metabolism studies, diabetes management and research, and obesity and health practices.

Wilding's frequent co-authors include:

  • Deepak L. Bhatt
  • Marc S. Sabatine
  • Lawrence A. Leiter
  • Darren K. McGuire
  • Itamar Raz

They have published extensively in several venues, with the highest number of publications appearing in:

  • Diabetes Obesity and Metabolism
  • Circulation
  • Diabetes Care
  • Diabetes
  • BMJ Open

Among their recent papers are:

  • Once-Weekly Semaglutide in Adults with Overweight or Obesity, 2021, New England Journal of Medicine
  • Definition and diagnostic criteria of clinical obesity, 2025, The Lancet Diabetes & Endocrinology
  • Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, 2022, Diabetes Obesity and Metabolism
  • Economic impacts of overweight and obesity: current and future estimates for 161 countries, 2022, BMJ Global Health
  • SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications, 2021, The Lancet

Best Publications

  • SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

    Thomas A Zelniker;Stephen D Wiviott;Itamar Raz;Kyungah Im

  • A role for glucagon-like peptide-1 in the central regulation of feeding

    M. D. Turton;D. O'Shea;I. Gunn;S. A. Beak

  • Once-Weekly Semaglutide in Adults with Overweight or Obesity.

    John P.H. Wilding;Rachel L. Batterham;Rachel L. Batterham;Salvatore Calanna;Melanie Davies

  • A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

    Xavier Pi-Sunyer;Arne Astrup;Ken Fujioka;Frank Greenway

  • Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation.

    G.A. Bray;K.K. Kim;J.P.H. Wilding

  • Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome

    Steven R Coughlin;Lynn Mawdsley;Julie A Mugarza;Peter M A Calverley

  • Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

    Jan Bolinder;Östen Ljunggren;Joel Kullberg;Lars Johansson;Lars Johansson

  • Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis

    Jay S. Skyler;George L. Bakris;Ezio Bonifacio;Tamara Darsow

  • Management of obesity

    George A Bray;Gema Frühbeck;Donna H Ryan;John P H Wilding

  • Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).

    Mikhail Kosiborod;Matthew A. Cavender;Alex Z. Fu;John P. Wilding

  • Food fails to suppress ghrelin levels in obese humans.

    P. J. English;M. A. Ghatei;I. A. Malik;S. R. Bloom

  • Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.

    Thomas A. Zelniker;Stephen D. Wiviott;Itamar Raz;KyungAh Im

  • 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

    Carel W le Roux;Carel W le Roux;Arne Astrup;Ken Fujioka;Frank Greenway

  • Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.

    Patrick M O'Neil;Andreas L Birkenfeld;Barbara McGowan;Ofri Mosenzon

  • Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.

    Ofri Mosenzon;Stephen D Wiviott;Avivit Cahn;Aliza Rozenberg

  • Anti-obesity drugs: past, present and future

    R. John Rodgers;Matthias H. Tschöp;John P. H. Wilding

  • Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.

    Eri T. Kato;Michael G. Silverman;Ofri Mosenzon;Thomas A. Zelniker

  • Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

    Wilding Jp;Woo;Soler Ng;Pahor A

  • Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.

    J. Bolinder;Östen Ljunggren;L. Johansson;L. Johansson;J. Wilding

  • A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers Applicability of a novel insulin-independent treatment

    John P.H. Wilding;Paul Norwood;Caroline T'joen;Arnaud Bastien

Frequent Co-Authors

Deepak L. Bhatt
Deepak L. Bhatt Mount Sinai Hospital
Stephen D. Wiviott
Stephen D. Wiviott Brigham and Women's Hospital
Marc S. Sabatine
Marc S. Sabatine Brigham and Women's Hospital
Itamar Raz
Itamar Raz Hebrew University of Jerusalem
Darren K. McGuire
Darren K. McGuire The University of Texas Southwestern Medical Center
Frank L. Greenway
Frank L. Greenway Pennington Biomedical Research Center
Sabina A. Murphy
Sabina A. Murphy Brigham and Women's Hospital
Lawrence A. Leiter
Lawrence A. Leiter University of Toronto
M. A. Ghatei
M. A. Ghatei Imperial College London
Carel W. le Roux
Carel W. le Roux University College Dublin

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering studying Medicine in the USA, there are several online degree options and career pathways that complement traditional medical studies. These programs are ideal for students seeking flexible schedules, lower costs, and diverse roles within the healthcare sector.

For those interested in medical administration, a low cost medical coding and billing online program offers a practical starting point. These programs equip students with essential skills to manage patient data, process insurance claims, and ensure the financial efficiency of healthcare facilities.

Nursing remains one of the most versatile healthcare professions. Aspiring nurses can choose from a range of affordable online nursing programs that lead to RN or BSN qualifications. Those wishing to advance their practice may consider the most affordable nurse practitioner programs, which train students to provide primary or specialized care.

For ambitious professionals aiming for leadership or research roles, pursuing postgraduate degrees like the cheapest dnp programs can open the door to advanced opportunities within healthcare systems and academia.

Best Scientists Citing John P.H. Wilding

Trending Scientists

Recently Published Articles